Toronto, Ontario

Endexo technology reduces potentially deadly complications with a new compound

Nominated by:

ERNEST C. MANNING AWARDS FOUNDATION

About the Innovation

Paul Santerre invented Endexo technology, a unique compound of surface-modifying macro molecules that are added to plastics during the manufacturing process of medical devices. The special coating helps reduce clotting when the devices are used to treat patients, reducing the risk of adverse reactions and potentially deadly complications. Now being used in commercialized products in Canada, the U.S. and Europe, Endexo is helping to improve treatment outcomes for thousands of patients.

About the Innovator

Professor Paul Santerre is a chemical engineer. In 2001, he co-founded Interface Biologics Inc., a Toronto-based health technologies company. He served as founding president until 2004, and currently sits as chief scientific officer and member of the board of directors. Mr. Santerre has been published widely in peer-reviewed journals and is a listed inventor on more than 60 patents in the area of polymers, biodegradation, surface modification and drug delivery. He has held several significant leadership portfolios at the University of Toronto, and is the recipient of numerous awards, including the Manning Award for Innovation/Entrepreneurship and a fellowship with the Canadian Academy of Health Sciences.

Paul Santerre

What are you looking for?